ReviewPharmaceutical nanotechnology2019
Novel Drug Delivery Strategies for the Treatment of Onychomycosis.
Review in Pharmaceutical nanotechnology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Trial
- Formulation and development of thymoquinone-loaded ufasome hydrogel for effective treatment of onychomycosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Nanocarriers in Ungual Drug Delivery.Pharmaceutics · 2025Review
- Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.RSC advances · 2025Review
- Novel Therapeutic Approaches Emerging in the Field of Onychomycosis.Recent advances in anti-infective drug discovery · 2025Review
- Correlation Between Nail Thickness and Onychomycosis: Misuse of Antifungal Agents in Patients With Thick Nails.Annals of dermatology · 2024Article
- Terbinafine in acrylic polymer for the treatment of onychomycosis in hemodialysis patients: a phase II clinical trial.Frontiers in medicine · 2024Article
- The Green Synthesis of Silver Nanoparticles fromPathogens (Basel, Switzerland) · 2023Article
- Contemporary Techniques and Potential Transungual Drug Delivery Nanosystems for The Treatment of Onychomycosis.AAPS PharmSciTech · 2023Review
- Hydroxypropyl chitosan nail lacquer of ciclopirox-PLGA nanocapsules for augmented in vitro nail plate absorption and onychomycosis treatment.Drug delivery · 2022Article
- Itraconazole and Difluorinated-Curcumin Containing Chitosan Nanoparticle Loaded Hydrogel for Amelioration of Onychomycosis.Biomimetics (Basel, Switzerland) · 2022Article
- Chitosan Nanoparticles Loaded Poloxamer 407 Gel for Transungual Delivery of Terbinafine HCl.Pharmaceutics · 2022Article
- Quality by Design Guided Development of Polymeric Nanospheres of Terbinafine Hydrochloride for Topical Treatment of Onychomycosis Using a Nano-Gel Formulation.Pharmaceutics · 2022Article
- The Unique Carboxymethyl Fenugreek Gum Gel Loaded Itraconazole Self-Emulsifying Nanovesicles for Topical Onychomycosis Treatment.Polymers · 2022Article
- Updated Perspectives on the Diagnosis and Management of Onychomycosis.Clinical, cosmetic and investigational dermatology · 2022Review
- In Silico Drug Screening Based Development of Novel Formulations for Onychomycosis Management.Gels (Basel, Switzerland) · 2021Article
- Constant Voltage Iontophoresis Technique to Deliver Terbinafine via Transungual Delivery System: Formulation Optimization Using Box-Behnken Design and In Vitro Evaluation.Pharmaceutics · 2021Article
- Application of central composite design for the optimization of itraconazole loaded nail lacquer formulation.3 Biotech · 2021Article
- Nanoliposome-loaded antifungal drugs for dermal administration: A review.Current medical mycology · 2021Article
- Human Nails Permeation of an Antifungal Candidate Hydroalcoholic Extract from the PlantMolecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Onychomycosis accounts for 50% of all nail disease cases and is commonly caused by dermatophytes. It was primarily considered a cosmetic problem but has been garnering attention lately due to its persistent nature and difficult treatment with relapses. With prolonged treatment duration and high cost involved in treating onychomycosis, several attempts have been made in overcoming the rigid nail barrier. The conventional treatment of onychomycosis involves oral and topical therapy. The oral antifungal agents though quite effective, are hepato-toxic and cause drug-drug interactions. Topical therapy is more patient compliant being devoid of such adverse effects but it suffers from another setback of improper nail penetration. Amorolfine and ciclopirox nail lacquers are popular market products. Since decades, efforts have been made to enhance topical delivery for efficiently treating onychomycosis. Mechanical, physical and chemical methods have been employed. Despite all the attempts made, the nail delivery issues are far from being solved. Recently, the focus has shifted to novel drug delivery systems like nanoparticles, microemulsions, polymeric films and nail lacquers for enhanced drug permeation and localized therapy. The research around the world is exploring their potential as effective treatment options. This review intends to further explore the novel delivery strategies to treat a persistent fungal infection like onychomycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.